A nonprofit publication of the Kentucky Center for Public Service Journalism

Pain Management Contract Agreement Icd 10


Berna C, Kulich RJ, Rathmell JP. Rejuvenation of long-term treatment of opioids in chronic non-cancerous pain: evidence and recommendations for daily practice. Mayo Clin Proc. 2015;90(6):828–42. Among the majority of our patients with CSA, the average dose of MME/day was below the level recommended by the CDC Directive for the prescribing of opioids for chronic pain [7]. This directive was intended for primary care patients who prescribe opioids for chronic pain outside of active cancer treatment, palliative care and end-of-life care [7]. The CDC Directive recommends that physicians “carefully reassess evidence of individual benefits and risks when considering increasing the dose to ≥50 mg/day of morphine-milligram (MME) per day, and avoid increasing the dose to ≥90 MG/day or carefully justify the decision to use it ≥90/MME day.” In our population, 21.5% received ≥50 MME/day and 9.7% ≥90 MME/day. The probability of opioid abuse in patients varies by dose, with estimated intermediate years of 0.7% with lower doses (≤36 MME/day) at higher doses (≥120 MME/day) compared to 0.004% in patients who did not prescribe opiates [7]. The objective of the ASCs is to strengthen compliance with “emergency contracts” that use written documents describing the expected behaviour and the consequences that result [32]. To the extent that they include compliance monitoring (for example. B drug evaluation, urine drug testing and number of pills), ASCs can reduce the risk of dose escalation and the development of opioid use disorders [17], although data are limited [11]. Nahin RL. Estimates of the prevalence of pain and severity in adults: United States, 2012.

J Pain Official J Am Pain Soc. 2015;16(8):769–80. Although many aspects of the contract system appear to have been successful, primary care physicians have often not monitored compliance with contracts. Less than 45% of patients (n -140) received UTS. There was no standardized protocol for UTS at the clinic. UTS at the physician`s discretion was positive for illegal drugs at 38% (53/140) of the patients tested, and was the most common reason for termination of the contract. It is likely that physicians ordered UTS from patients who suspected a higher risk of substance abuse. The general ability of physicians to acknowledge non-compliance with treatment plans is poor.24 In the absence of a clear drug screening directive, some abuse may not have been recognized. While drug screening is widely supported, there is very little data on its use in clinical settings25,26. that UTS may be more effective in identifying non-follower patients than monitoring behaviours alone or self-reporting of drug use alone.27 Reports from 2 academic medical centers with different populations like ours found 38% 3 and 32% 4 prevalence of substance abuse in their chronic pain population, according to our study. Since we have not identified clinical predictors for termination of the contract, a more structured testing strategy, with defined interpretation criteria for UTS, would provide valuable information for both diagnostic and therapeutic decisions regarding substance abuse and contract cancellation.

The medication contract is described in Figure 1 and includes the responsibility of the patient and the physician. In addition to the diagnosis, nature and dose of prescribed medications, the conditions under which opioids are prescribed or not, and patient responsibility have been defined. Random urine drug testing would be conducted if recommended by the physician to monitor compliance and possible use of illicit substances. Patients were informed that if patient liability was not met, the contract would be terminated. The duties of the physician and/or hospital staff included providing monthly prescriptions on the due date, monitoring the effects of therapy and continuing care.


Recent Posts

Comments are closed.